{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-013949","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.718551+00:00","generated_at":"2026-06-15T04:12:06.809226+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulse Biosciences Q1 net loss narrows to $9.8M; $65M private placement with Executive Chairman","bullets":["GAAP net loss of $9.8M vs $17.3M YoY; non-GAAP net loss of $8.6M vs $14.2M.","Cash and equivalents $54.1M as of March 31, 2023, up from $12.7M a year ago.","Entered $65M private placement with Executive Chairman Robert Duggan, canceling all indebtedness.","Appointed Dr. Gan Dunnington as Chief Medical Officer, Cardiac Surgery.","Completed FDA pre-submission for nsPFA surgical ablation clamp; advancing preclinical studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-013949","json":"https://secwatch.observer/filing/0001437749-23-013949.json","markdown":"https://secwatch.observer/filing/0001437749-23-013949.md","text":"https://secwatch.observer/filing/0001437749-23-013949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923013949/0001437749-23-013949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923013949/plse20230510_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:12:06.809226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"117a32fb821185fa069f55870b02cac0bb1f1d63","claim":"PULSE BIOSCIENCES, INC. reported the fiscal quarter ended March 31, 2023 results: net income ($9.8) million.","evidence_excerpt":"GAAP net loss for the three months ended March 31, 2023, was ($9.8) million compared to ($17.3) million for the three months ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923013949/0001437749-23-013949-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended March 31, 2023"},{"label":"Net income","value":"($9.8) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}